Nanjing Leads Biolabs to Present Opamtistomig Phase IIb Data at ESMO 2026

Nanjing Leads Biolabs Co., Ltd. (9887.HK) said on September 22, 2026, that its pivotal registrational Phase IIb trial of opamtistomig (LBL-024) will be presented at ESMO 2026. The study evaluates the drug as a monotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The clinical-stage biotechnology company did not disclose efficacy or safety results in the announcement. Presentation of pivotal registrational data at a major oncology congress typically precedes regulatory filing decisions for the candidate. Trading in Hong Kong-listed shares of Nanjing Leads Biolabs may draw investor attention given the potential regulatory implications of the Phase IIb readout.